World Tuberculosis Day serves as a poignant reminder to raise awareness about tuberculosis (TB). Despite the efforts and promising developments in the fight against this disease, TB remains an [...]
MTBVAC, the Spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, reaches a new milestone by starting clinical trials in India, the [...]
The Bill & Melinda Gates Medical Research Institute (Gates MRI) today (19 March 2024) announced that a Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine [...]
March 2024 – The TBVI Governance Board is pleased to announce the appointment of a new Executive Director of the organisation. Tuberculosis (TB) stands as one of the most persistent and [...]
On January 30-31, 2024, the TBVI Symposium was held in Les Diablerets, Switzerland. This year, the symposium brought together over 120 tuberculosis (TB) vaccine researchers, developers, funders [...]
Please find below the Programme TBVI Symposium 2024 for the TBVI symposium 2024, which will be held on January 30 and 31, 2024 in Les Diablerets. Tuesday January 30, 2024 (Maison des congrès) [...]
Runderweg 6
8219 PK Lelystad
The Netherlands
Email: info@tbvi.eu
Phone: 0031 (0)6 1099 5196
